Advanced search
Start date
Betweenand


Neutralizing antibody responses after a two-dose regimen with BNT162b2 CoronaVac or ChAdOx1-S in Brazil: Differential neutralization of SARS-CoV-2 omicron variants

Full text
Author(s):
Show less -
Daher, Isabela Pazotti ; Almeida, Bianca da Silva ; de Souza-Silva, Guilherme Antonio ; Marques, Rodolfo Ferreira ; Soares, Gustavo Henrique Correa ; Andreata-Santos, Robert ; Moretti, Ana ; Silva, Mariangela de Oliveira ; Schuch, Viviane ; Sasahara, Greyce Luri ; Kuramoto, Andreia ; Yamamoto, Marcio ; Ferreira, Luis Carlos de Souza ; Santos, Keity ; Coelho, Veronica P. C. V. ; Kalil, Jorge ; Rosa, Daniela Santoro ; Cunha-Neto, Edecio ; Boscardin, Silvia Beatriz
Total Authors: 19
Document type: Journal article
Source: Clinical Immunology; v. 276, p. 12-pg., 2025-07-01.
Abstract

The emergence of SARS-CoV-2 variants has reduced antibody effectiveness, affecting vaccine protection. This study evaluated neutralizing antibodies against Wuhan strain and several variants, including Alpha, Beta, Gamma, Delta, and Omicron, in Brazilians vaccinated twice with CoronaVac, ChAdOx1-S, or BNT162b2 before Delta and Omicron emerged. After the booster, strong antibody responses to the Wuhan strain were seen in all groups, but BNT162b2 resulted in higher anti-Spike and anti-RBD IgG levels. While all vaccines showed some cross-neutralization against Alpha, Beta, Gamma, and Delta, only BNT162b2 was effective against Omicron BA.2 and BA.4/5 subvariants. Furthermore, BNT162b2 vaccination showed a positive correlation between Wuhan RBD-specific IgG and Omicron neutralizing antibodies. This group demonstrated distinct clustering patterns of neutralizing antibodies against all variants, unlike those from CoronaVac and ChAdOx1-S. The findings suggest BNT162b2 offers broader neutralization capability, highlighting the benefit of booster shots with bivalent mRNA vaccines to enhance immune responses against emerging variants. (AU)

FAPESP's process: 21/14197-7 - Neutralizing antibodies against different SARS-CoV-2 variants of concern in convalescent and immunized individuals with different COVID-19 vaccines
Grantee:Isabela Pazotti Daher
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 14/50890-5 - INCT of Investigation in Immunology
Grantee:Jorge Elias Kalil Filho
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 21/13004-0 - Development of subunit vaccines against SARS-CoV-2 based on the receptor binding domain (RBD)
Grantee:Daniela Santoro Rosa
Support Opportunities: Regular Research Grants
FAPESP's process: 18/07142-9 - Influence of STAT1, STAT3, STAT5 and STAT6 Signaling Pathways on Conventional Dendritic Cells in the Instruction of the T-Cell Auxiliary Response
Grantee:Silvia Beatriz Boscardin
Support Opportunities: Regular Research Grants
FAPESP's process: 20/05204-7 - Development of SARS-CoV-2 auto-assembly protein-based nanovaccines
Grantee:Luis Carlos de Souza Ferreira
Support Opportunities: Regular Research Grants